# PK and PD of Single, Escalating Doses of PER977 Following Enoxaparin

> **NCT02206100** · PHASE1,PHASE2 · COMPLETED · sponsor: **Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.** · enrollment: 40 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** PER977
- **DRUG:** Placebo
- **DRUG:** enoxaparin

## Key facts

- **NCT ID:** NCT02206100
- **Lead sponsor:** Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2020-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02206100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02206100, "PK and PD of Single, Escalating Doses of PER977 Following Enoxaparin". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02206100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*